Table 1.
General characteristics of the population.
| Mean/median | Range/SD | |
|---|---|---|
| Age | ||
| Patients (n = 184) | 70.71/71 | 49–92/8.3 |
| Spouses (n = 137) | 68.3/68 | 45–87/7.9 |
|
| ||
| Time since diagnosis (months): | 33.3/18 | 2–142/34.27 |
|
| ||
| PSA (ng/ml) | 2.88/0.1 | 0–88/12.18 |
|
| ||
| VAS | 0.42/0 | 0–2/0.54 |
| VAS 0: n = 112 (60.9%) | ||
| VAS 1: n = 67 (36.4%) | ||
| VAS 2: n = 5 (2.7%) | ||
|
| ||
| Patient education level | Spouse education level | |
| Elementary: n = 99 (53.8%) | Elementary: n = 88 (64.2%) | |
| High school: n = 68 (37%) | High school n = 37 (27%) | |
| University: n = 17 (9.2%) | University: n = 12 (8.8%) | |
|
| ||
| Comorbidities: | None: 40 (21.7%) | |
| Cormob 1: 58 (31.5%) | ||
| Comorb 2: 64 (34.9%) | ||
| Mean: 1.36 | Comorb 3 or more: 22 (11.9%) | |
| Median: 1 | ||
|
| ||
| Stage (∗) | ||
| Localized n = 117 (63.7%) | ||
| L. advanced n = 33 (17.9%) | ||
| MTX n = 24 (13%) | ||
| CRPC n = 10 (5.4%) | ||
|
| ||
| Primary treatment (∗∗) | Time since diagnosis (months): | |
| AS (n = 20; 10.9%) | 33.29 (median: 18), range: 2–142 | |
| RP (n = 99: 53.8%) | 55.9 (median: 48), range: 11–132 | |
| RT (n = 16: 8.7%) | 30.5 (median: 18), range: 2–142 | |
| HT (n = 49: 26.6%) | 12.8 (median: 12), range: 2–28 | |
| ST: n = 41 (22.3%) | 39.8 (median: 23), range: 3–138 | |
∗MTX: metastatic; CRPC: Castrate-resistant prostate cancer. ∗∗AS: active surveillance; RP: radical prostatectomy; RT: radiotherapy; HT: hormone therapy; ST: sequential treatment.